Rivaroxaban Use for Thrombosis Prophylaxis Is Associated With Early Periprosthetic Joint Infection

The Journal of Arthroplasty
Olubusola BrimmoCarlos A Higuera

Abstract

Periprosthetic joint infection is a disastrous complication after total hip arthroplasty (THA) and total knee arthroplasty (TKA). The use of certain agents to prevent deep vein thrombosis after arthroplasty has been linked to an increased risk of adverse effects including wound drainage and infection. Adverse effects of one alternative, rivaroxaban, was studied in a single community hospital. International Classification of Diseases, Clinical Modification 9 codes were used to identify primary THAs and TKAs in an administrative database at one large-volume community hospital performed in 2012. Patients were divided into 2 groups: the study group received rivaroxaban, whereas the control group received another form of chemical thromboprophylaxis for at least 2 weeks postoperative. Demographics, risk factors, and illness severity scores were collected for each group. The primary measured outcome was the incidence of deep surgical site infection (SSI) within 30 days postoperative. A total of 639 TKA or THA patients were included, with 159 patients who received rivaroxaban and 480 who received another form of chemical thromboprophylaxis. There were no significant differences between groups regarding demographics, risk factors, or il...Continue Reading

References

Nov 25, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E F BerbariD R Osmon
May 2, 2001·Journal of Chemotherapy·L LazzariniF de Lalla
Jan 31, 2002·Acta Orthopaedica Scandinavica·L Lidgren
Apr 6, 2006·International Orthopaedics·A M ByrneJ M O'byrne
Jun 27, 2006·The Journal of Bone and Joint Surgery. British Volume·J E PhillipsR J Grimer
Jun 7, 2008·The Journal of Arthroplasty·Steven M KurtzJavad Parvizi
Jun 27, 2008·The New England Journal of Medicine·Bengt I ErikssonUNKNOWN RECORD1 Study Group
Jun 27, 2008·The New England Journal of Medicine·Michael R LassenUNKNOWN RECORD3 Investigators
Nov 14, 2008·The New England Journal of Medicine·Edward P Schuman
Oct 31, 2012·The Journal of Bone and Joint Surgery. British Volume·M R LassenA G G Turpie
Feb 16, 2013·European Journal of Orthopaedic Surgery & Traumatology : Orthopédie Traumatologie·Katia SindaliRaj Shrivastava

❮ Previous
Next ❯

Citations

Jul 19, 2017·The Journal of Bone and Joint Surgery. American Volume·Antonia F ChenAlex McLaren
Jun 24, 2017·Anesthesia and Analgesia·Ronald J Gordon, Frederick W Lombard
Sep 9, 2017·Hip International : the Journal of Clinical and Experimental Research on Hip Pathology and Therapy·Sura H Hamza, Paul Reynolds
Jul 17, 2018·Journal of Orthopaedic Surgery·Bryon Jun Xiong TeoAndrew Hwee Chye Tan
Jul 1, 2020·The Bone & Joint Journal·Alejandro Gonzalez Della ValleEduardo A Salvati
Mar 21, 2017·European Journal of Orthopaedic Surgery & Traumatology : Orthopédie Traumatologie·Dimitrios V PapadopoulosAnastasios V Korompilias
Jul 27, 2018·Research and Practice in Thrombosis and Haemostasis·Silvio Antoniak
Sep 20, 2017·The Journal of Bone and Joint Surgery. American Volume·James T NinomiyaStephen J Incavo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2022 Meta ULC. All rights reserved